Alnylam PharmaceuticalsLTS:0HD2 +0.82%67 Gross Margin % is 81.91% as of Mar. 2026, which is 2% below its 10-year median of 83.95. GuruFocus rates LTS:0HD2 with a GF Score™ of 67/100 and a GF Value™ of $519.03 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 735 Biotechnology companies, Alnylam Pharmaceuticals ranks better than 73.2% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Alnylam Pharmaceuticals had a gross margin of 81.91% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Alnylam Pharmaceuticals Gross Margin % Related Terms
Alnylam Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HD2 vs RVMD, ONC, MRNA: Gross Margin % Comparison
For the Biotechnology subindustry, Alnylam Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Alnylam Pharmaceuticals (LTS:0HD2) has a Gross Margin % of 81.91% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Alnylam Pharmaceuticals and its competitors. This is near median its historical median of 83.95. Over the past decade, Alnylam Pharmaceuticals' Gross Margin % has ranged from 80.83 to 97.59. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #197 out of 735 companies in the Biotechnology industry, placing it in the top 26.8%.
Is Alnylam Pharmaceuticals' Gross Margin % too high?
Alnylam Pharmaceuticals' current Gross Margin % of 81.91% is near median its 10-year median of 83.95. Over the past 10 years, this metric has ranged from a low of 80.83 to a high of 97.59. The Biotechnology industry median Gross Margin % is 60.90. Alnylam Pharmaceuticals' value of 81.91% is 34.5% above this industry median. Based on the distribution chart, Alnylam Pharmaceuticals ranks #197 out of 735 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alnylam Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Gross Margin % compare to RVMD and ONC?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #197 out of 735 companies for Gross Margin %. This puts Alnylam Pharmaceuticals in the upper half of its industry. The industry median Gross Margin % is 60.90. Alnylam Pharmaceuticals' value of 81.91% is 34.5% above this benchmark. Historically, Alnylam Pharmaceuticals' own Gross Margin % has ranged from 80.83 to 97.59 over the past decade. While the company's 10-year median is 83.95 vs. the industry median of 60.90, Alnylam Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alnylam Pharmaceuticals's current Gross Margin % of 81.91% is 34.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Alnylam Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alnylam Pharmaceuticals's current Gross Margin % is 81.91%, which is near median its own 10-year median of 83.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $519.03, compared to a current price of $294.37 — trading 43.3% below its estimated fair value. The current Gross Margin % is 81.91%, which is near median its 10-year median of 83.95 and 34.5% above the Biotechnology industry median of 60.90. Alnylam Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Gross Margin % is 81.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $294.37 is trading 43.3% below its estimated GF Value™ of $519.03.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
Gross Margin %: 81.91% (near median its 10-year median of 83.95)
GF Value™: $519.03 vs. price of $294.37 (43.3% below fair value)
Industry Position: 34.5% above the Biotechnology median (#197 of 735)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
67GF Score
Get the complete analysis for LTS:0HD2
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
